This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Clinical data on primary prevention with aspirin were derived from two published meta-analyses of five clinical trials. Data on secondary prevention with aspirin were retrieved from the CAPRIE trial (clopidogrel versus aspirin in patients at risk of ischaemic events).
Methods used to judge relevance and validity, and for extracting data
It was not stated whether the primary studies were identified selectively or through a systematic review of the literature. However, the choice of meta-analyses of clinical trials ensures a high internal validity of the clinical estimates.
Measure of benefits used in the economic analysis
The summary benefit measure used was the life-years (LYs). These were estimated using the decision model. An annual discount rate of 3% was applied to future benefits.
Direct costs
The analysis of costs was carried out from the perspective of the public health insurer. It included the costs associated with aspirin use and CVD events (including fatal and nonfatal stroke or myocardial infarction, gastrointestinal bleeding and follow-up of CVD events). The unit costs and the resource quantities were not presented separately, but the cost items were presented as macro-categories. The source of the resource use data was not explicitly reported. The costs came from Japanese sources such as the Ministry of Health, Labor and Welfare, as well as a survey of medical care activities in public health insurance and a patient survey. The price year was not explicitly reported. Discounting was relevant, as 10-year costs were evaluated, and an annual rate of 3% was used.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The productivity costs were not included.
Currency
Japanese yen (JPY). The costs were converted in euros (EUR) at the rate EUR 1 = JPY 130.
Sensitivity analysis
The robustness of the cost-effectiveness results was tested in univariate sensitivity analyses. The model inputs varied were the annual risk of CHD, cost of stroke treatment, time horizon, gastrointestinal bleeding rate, stroke rate, cost of each event and discounting. The sources of the alternative values were not reported, but they appear to have been based on authors' assumptions.
Estimated benefits used in the economic analysis
Over a 10-year time horizon, 8.36 LYs were associated with aspirin and 8.33 LYs with no aspirin (difference 0.03).
Cost results
The 10-year total cost of care from the viewpoint of the public health insurer was JPY 634,000 (EUR 4,857) with no aspirin and JPY 518,000 (EUR 3,968) with aspirin. The difference was JPY 116,000 (EUR 889) (95% confidence interval: JPY 57,077 to JPY 175,151). Thus, the extra cost of aspirin was more than offset by a reduction in the costs associated with CVD events.
Synthesis of costs and benefits
An incremental analysis was performed in order to combine the costs and benefits of the alternative strategies. However, an incremental cost-effectiveness ratio was not calculated as aspirin was the dominant strategy, being more effective and less expensive than no aspirin.
The sensitivity analysis corroborated the base-case findings. Specifically, for any level of CHD risk higher than 0.20% (it was 1.5% in the base-case), aspirin was the dominant strategy. A similar conclusion was reached regardless of the variation in the cost of stroke or other model inputs. Cost-savings increased as the time horizon of the model increased.
Authors' conclusions
Low-dose aspirin administered as primary prevention in patients at increased risk of cardiovascular disease (CVD) was effective and cost-saving from the perspective of the Japanese insurer. Savings were observed as early as in the first year of treatment.
CRD COMMENTARY -Selection of comparators
The selection of the comparator (i.e. no aspirin) was appropriate as it represented the conventional pattern of care in Japan. You should decide whether this is a valid comparator in your own setting.
Validity of estimate of measure of effectiveness
The clinical data used to populate the decision model were derived from high-quality sources. In effect, two metaanalyses of clinical trial and a randomised, clinical trial were selected. It was not stated whether these studies were identified selectively, but no details of a systematic review of the literature were provided. The authors did not provide any information on the primary studies. However, they did state that the primary studies (original clinical trials) were not homogeneous in terms of aspirin dose or CHD baseline risk.
Validity of estimate of measure of benefit
Survival, which was estimated using a modelling approach, represents an appropriate benefit measure. It can also be compared with the benefits of other health care interventions. The impact of the preventive strategy on quality of life was not investigated. Discounting was appropriately performed.
Validity of estimate of costs
The analysis of the costs was consistent with the perspective of the study. The costs were presented as macro-categories and a breakdown of the cost items was not given for each category. This may limit the possibility of replicating the analysis in other settings. The authors stated that the costs of co-administration, of anti-acids for example, were not considered. The sources of the costs were reported, but information on the sources of resource use was less clear. Statistical analyses of the costs were not carried out, but key cost items were varied in the sensitivity analysis. The price year was not reported, which will make reflation exercises in other time periods difficult.
